Risk of bladder cancer in patients with type 2 diabetes mellitus: a retrospective population-based cohort study in Lithuania.
Antihyperglycemic therapy
Bladder cancer
Cancer risk
Cohort study
Type 2 diabetes mellitus
Journal
Cancer causes & control : CCC
ISSN: 1573-7225
Titre abrégé: Cancer Causes Control
Pays: Netherlands
ID NLM: 9100846
Informations de publication
Date de publication:
21 Sep 2024
21 Sep 2024
Historique:
received:
20
08
2023
accepted:
21
08
2024
medline:
21
9
2024
pubmed:
21
9
2024
entrez:
21
9
2024
Statut:
aheadofprint
Résumé
The objective of our study was to evaluate bladder cancer risk among Lithuanian type 2 diabetes mellitus (T2DM) patients and the effect of antihyperglycemic therapy on bladder cancer risk. We analyzed bladder cancer risk in a cohort of patients who were diagnosed with T2DM between 2001 and 2012 in Lithuania. Bladder cancer risk in four groups of antihyperglycemic medication users (insulin-only, metformin-only, sulfonylurea-only, and pioglitazone ± any other drug) was also assessed. Standardized incidence ratios for bladder cancer were calculated. A total of 76,818 patients (28,762 males and 48,056 females) with T2DM were included in the final cohort. In the whole cohort of diabetic patients, 277 bladder cancer cases were observed, compared to 232.75 expected cases, according to bladder cancer rates in the general population (Standardized Incidence Ratio 1.19; 95% Confidence Interval: 1.06-1.34). Higher risk of bladder cancer was found in both men and women; however, in women the risk increase was not statistically significant. We found higher risk of bladder cancer in patients of both sexes diagnosed with T2DM at the age of 50-79 years and also in all groups of different antihyperglycemic medication users. T2DM was associated with increased risk of bladder cancer.
Identifiants
pubmed: 39305342
doi: 10.1007/s10552-024-01911-2
pii: 10.1007/s10552-024-01911-2
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s).
Références
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A et al (2021) Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71(3):209–249
doi: 10.3322/caac.21660
pubmed: 33538338
Cumberbatch MGK, Jubber I, Black PC, Esperto F, Figueroa JD, Kamat AM et al (2018) Epidemiology of bladder cancer: a systematic review and contemporary update of risk factors in 2018. Eur Urol 74(6):784–795
doi: 10.1016/j.eururo.2018.09.001
pubmed: 30268659
Gill E, Sandhu G, Ward DG, Perks CM, Bryan RT (2021) The sirenic links between diabetes, obesity, and bladder cancer. Int J Mol Sci 22(20):11150
doi: 10.3390/ijms222011150
pubmed: 34681810
pmcid: 8539374
Wang M, Yang Y, Liao Z (2020) Diabetes and cancer: epidemiological and biological links. World J Diabetes 11(6):227–238.
doi: 10.4239/wjd.v11.i6.227
Giovannucci E, Harlan DM, Archer MC, Bergenstal RM, Gapstur SM, Habel LA et al (2010) Diabetes and cancer: a consensus report. Diabetes Care 33(7):1674–1685
doi: 10.2337/dc10-0666
pubmed: 20587728
pmcid: 2890380
Ahmadinezhad M, Arshadi M, Hesari E, Sharafoddin M, Azizi H, Khodamoradi F (2022) The relationship between metabolic syndrome and its components with bladder cancer: a systematic review and meta-analysis of cohort studies. Epidemiol Health 44:e2022050
doi: 10.4178/epih.e2022050
pubmed: 35638225
pmcid: 9684010
Rastad H, Parsaeian M, Shirzad N, Mansournia MA, Yazdani K (2019) Diabetes mellitus and cancer incidence: the Atherosclerosis Risk in Communities (ARIC) cohort study. J Diabetes Metab Disord 18(1):65–72
doi: 10.1007/s40200-019-00391-5
pubmed: 31275876
pmcid: 6582039
Ogunleye AA, Ogston SA, Morris AD, Evans JMM (2009) A cohort study of the risk of cancer associated with type 2 diabetes. Br J Cancer 101(7):1199–1201
doi: 10.1038/sj.bjc.6605240
pubmed: 19690547
pmcid: 2768085
International Diabetes Federation. Diabetes data report 2000–2045. IDF Diabetes atlas 10th edition 2021. Accessed on 30 November 2022. Available from: https://diabetesatlas.org/
Rey-Reñones C, Baena-Díez JM, Aguilar-Palacio I, Miquel C, Grau M (2021) Type 2 diabetes mellitus and cancer: epidemiology, physiopathology and prevention. Biomedicines 9(10):1429
doi: 10.3390/biomedicines9101429
pubmed: 34680546
pmcid: 8533606
Dankner R, Roth J (2020) More recent, better designed studies have weakened links between antidiabetes medications and cancer risk. Diabet Med J Br Diabet Assoc 37(2):194–202
doi: 10.1111/dme.14179
Liu CQ, Sun JX, Xu JZ, Qian XY, Hong SY, Xu MY et al (2022) Metformin use on incidence and oncologic outcomes of bladder cancer patients with T2DM: an updated meta-analysis. Front Pharmacol 13:865988
doi: 10.3389/fphar.2022.865988
pubmed: 35462910
pmcid: 9021395
Tang H, Shi W, Fu S, Wang T, Zhai S, Song Y et al (2018) Pioglitazone and bladder cancer risk: a systematic review and meta-analysis. Cancer Med 7(4):1070–1080
doi: 10.1002/cam4.1354
pubmed: 29476615
pmcid: 5911601
Larsson SC, Orsini N, Brismar K, Wolk A (2006) Diabetes mellitus and risk of bladder cancer: a meta-analysis. Diabetologia 49(12):2819–2823
doi: 10.1007/s00125-006-0468-0
pubmed: 17021919
Zhu Z, Zhang X, Shen Z, Zhong S, Wang X, Lu Y et al (2013) Diabetes mellitus and risk of bladder cancer: a meta-analysis of cohort studies. PloS One 8(2):e56662.
doi: 10.1371/journal.pone.0056662
pubmed: 23437204
pmcid: 3577653
Zhu Z, Wang X, Shen Z, Lu Y, Zhong S, Xu C (2013) Risk of bladder cancer in patients with diabetes mellitus: an updated meta-analysis of 36 observational studies. BMC Cancer 13:310.
doi: 10.1186/1471-2407-13-310
pubmed: 23803148
pmcid: 3699355
Xu X, Wu J, Mao Y, Zhu Y, Hu Z, Xu X et al (2013) Diabetes mellitus and risk of bladder cancer: a meta-analysis of cohort studies. PLoS ONE 8(3):e58079
doi: 10.1371/journal.pone.0058079
pubmed: 23472134
pmcid: 3589481
Fang H, Yao B, Yan Y, Xu H, Liu Y, Tang H et al (2013) Diabetes mellitus increases the risk of bladder cancer: an updated meta-analysis of observational studies. Diabetes Technol Ther 15(11):914–922
doi: 10.1089/dia.2013.0131
pubmed: 24180357
pmcid: 3817892
Yang XQ, Xu C, Sun Y, Han RF (2013) Diabetes mellitus increases the risk of bladder cancer: an updated meta-analysis. Asian Pac J Cancer Prev APJCP 14(4):2583–2589
doi: 10.7314/APJCP.2013.14.4.2583
pubmed: 23725179
Xu Y, Huo R, Chen X, Yu X (2017) Diabetes mellitus and the risk of bladder cancer: a PRISMA-compliant meta-analysis of cohort studies. Medicine (Baltimore) 96(46):e8588
doi: 10.1097/MD.0000000000008588
pubmed: 29145273
Chen HF, Chen SW, Chang YH, Li CY (2015) Risk of malignant neoplasms of kidney and bladder in a cohort study of the diabetic population in Taiwan with age, sex, and geographic area stratifications. Medicine (Baltimore) 94(38):e1494
doi: 10.1097/MD.0000000000001494
pubmed: 26402804
Hemminki K, Li X, Sundquist J, Sundquist K (2010) Risk of cancer following hospitalization for type 2 diabetes. Oncologist 15(6):548–555
doi: 10.1634/theoncologist.2009-0300
pubmed: 20479278
pmcid: 3227990
Hu J, Chen JB, Cui Y, Zhu YW, Ren WB, Zhou X et al (2018) Association of metformin intake with bladder cancer risk and oncologic outcomes in type 2 diabetes mellitus patients: a systematic review and meta-analysis. Medicine (Baltimore) 97(30):e11596
doi: 10.1097/MD.0000000000011596
pubmed: 30045293
pmcid: 6078654
Mamtani R, Pfanzelter N, Haynes K, Finkelman BS, Wang X, Keefe SM et al (2014) Incidence of bladder cancer in patients with type 2 diabetes treated with metformin or sulfonylureas. Diabetes Care 37(7):1910–1917
doi: 10.2337/dc13-1489
pubmed: 24496803
pmcid: 4067396
Ripamonti E, Azoulay L, Abrahamowicz M, Platt RW, Suissa S (2019) A systematic review of observational studies of the association between pioglitazone use and bladder cancer. Diabet Med J Br Diabet Assoc 36(1):22–35
doi: 10.1111/dme.13854
Cumberbatch MG, Rota M, Catto JW, La Vecchia C (2016) The role of tobacco smoke in bladder and kidney carcinogenesis: a comparison of exposures and meta-analysis of incidence and mortality risks. Eur Urol 70:458–466
doi: 10.1016/j.eururo.2015.06.042
pubmed: 26149669
Clair C, Meigs JB, Rigotti NA (2013) Smoking behavior among US adults with diabetes or impaired fasting glucose. Am J Med 126(6):541.e15–8
doi: 10.1016/j.amjmed.2012.11.029
pubmed: 23597801
Cignarelli A, Genchi VA, Caruso I, Natalicchio A, Perrini S, Laviola L et al (2018) Diabetes and cancer: pathophysiological fundamentals of a ‘dangerous affair.’ Diabetes Res Clin Pract 143:378–388
doi: 10.1016/j.diabres.2018.04.002
pubmed: 29679627
Chiefari E, Mirabelli M, La Vignera S, Tanyolaç S, Foti DP, Aversa A et al (2021) Insulin resistance and cancer: in search for a causal link. Int J Mol Sci 22(20):11137
doi: 10.3390/ijms222011137
pubmed: 34681797
pmcid: 8540232
Zhao H, Grossman HB, Spitz MR, Lerner SP, Zhang K, Wu X (2003) Plasma levels of insulin-like growth factor-1 and binding protein-3, and their association with bladder cancer risk. J Urol 169(2):714–717
doi: 10.1016/S0022-5347(05)63999-7
pubmed: 12544349
Stocks T, Rapp K, Bjørge T, Manjer J, Ulmer H, Selmer R et al (2009) Blood glucose and risk of incident and fatal cancer in the metabolic syndrome and cancer project (Me-Can): analysis of six prospective cohorts. PLoS Med 6(12):e1000201
doi: 10.1371/journal.pmed.1000201
pubmed: 20027213
pmcid: 2791167